SIRT1 and myeloid sarcoma: We previously showed that RSV and other SIRT1 activators reduce RGC loss in EAE models of optic neuritis (Shindler et al., 2007, 2010; Fonseca-Kelly et al., 2012), and therefore provide an important potential therapy to prevent the neuronal damage that leads to permanent neurologic disability in optic neuritis and MS patients.